Oftan (Timolol Maleate)

Timolol Maleate, the active ingredient in Oftan, is a beta‑blocker presented as a 0.5% ophthalmic solution for topical ocular use. It lowers intra‑ocular pressure and is used to manage glaucoma and ocular hypertension in adults. GNH USA supplies Oftan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Timolol maleate acts on ocular fluid dynamics to reduce intra‑ocular pressure, making it useful in several eye‑pressure disorders. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: reduces pressure to prevent progression to glaucoma. - Secondary glaucoma (e.g., pseudoexfoliative): helps control pressure when other mechanisms are involved.

Timolol maleate may cause ocular and systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation upon instillation. - Blurred vision shortly after use. - Dry eye or foreign‑body sensation. - Mild conjunctival hyperemia. - Temporary reduction in pupil size. - Mild headache.

Serious or Rare Side Effects: - Bradycardia or heart block. - Bronchospasm, especially in asthmatic patients. - Severe hypotension. - Allergic contact dermatitis of the eyelid. - Visual disturbances such as decreased visual acuity. - Systemic hypoglycaemia in diabetic patients.

Timolol maleate requires careful consideration of patient‑specific factors before use. - Cardiac monitoring: assess heart rate and rhythm in patients with cardiac disease. - Respiratory caution: avoid in patients with asthma or chronic obstructive pulmonary disease. - Diabetes awareness: monitor blood glucose as systemic absorption may mask hypoglycaemia. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Drug discontinuation: taper under medical supervision to avoid rebound intra‑ocular pressure rise. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Timolol maleate can interact with systemic and ocular agents, influencing its safety profile.

Major Interactions (Avoid): - Other non‑selective beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (e.g., verapamil): increased risk of heart block. - Antihypertensive agents: may cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely): - Inhaled beta‑agonists (e.g., albuterol): may reduce bronchodilator efficacy. - Antidiabetic drugs: timolol may mask hypoglycaemic symptoms. - NSAIDs: potential for reduced renal perfusion when combined with systemic beta‑blockade.